

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Takashi Shoda, President and Representative Director  
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Toshiaki Sai, General Manager,  
Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

## **Broad-spectrum Oral Antibacterial Agent**

### **Gracevit<sup>®</sup> Tablets 50mg/Fine Granules 10% Launched**

Tokyo, June 2, 2008 – DAIICHI SANKYO COMPANY, LIMITED (hereafter; DAIICHI SANKYO) announced that it launched the broad-spectrum antibacterial agent Gracevit<sup>®</sup> tablets 50mg/fine granules 10% (generic name: sitafloxacin hydrate). Gracevit<sup>®</sup> received approval for manufacture and marketing from the Japanese Ministry of Health, Labour and Welfare on January 25 and attained the National Health Insurance (NHI) drug price listing on April 18.

DAIICHI SANKYO currently markets Cravit<sup>®</sup>, which is highly acclaimed for its clinical efficacy and safety in tablet form and as a fine granular preparation. However, Gracevit<sup>®</sup> exhibits potent antibacterial activity with a broad spectrum and is expected to be the new quinolone oral antibacterial agent, clinically effective in severe cases of bacterial infection, relapse/recrudescence of infection and infections where resistant bacteria are the suspected cause.

Promoting drug compliance and ensuring safety for Gracevit<sup>®</sup> are top priorities for DAIICHI SANKYO and the company is set to provide information for these purposes. In addition to Cravit<sup>®</sup>, DAIICHI SANKYO is confident Gracevit<sup>®</sup> can further contribute to the treatment of infectious diseases.